UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): March 16, 2022

iBio, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)


001-35023	26-2797813
(Commission File Number)	(IRS Employer Identification No.)

8800 HSC Parkway

Bryan, TX 77807

(Address of principal executive offices and zip code)

(979) 446-0027

(Registrant’s telephone number including area code)

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	IBIO	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

iBio, Inc. (the “Company”) will be making several presentations to investors over the next several weeks. In connection with the presentations, the Company intends to discuss the investor presentation, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and in the investor presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

The investor presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.

The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.

Item 8.01. Other Events.

As previously reported by the Company in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on August 27, 2021 (the “August 2021 Form 8-K”), on August 23, 2021, the Company entered into a series of agreements with RubrYc Theraputics, Inc. (“RubrYc”) described in more detail in the August 2021 Form 8-K whereby in exchange for a $5 million investment in RubrYc, a potential further investment of $2.5 million, potential future milestones and royalties, the Company acquired:

•A worldwide exclusive license to certain antibodies that RubrYc developed under what it calls its RTX-003 campaign, which are promising immuno-oncology antibodies that bind to the CD25 protein without interfering with the IL-2 signaling pathway thereby potentially depleting T regulatory (T reg) cells while enhancing T effector (T eff) cells and encouraging the immune system to attack cancer cells

•Options for iBio to license additional antibodies developed using RubrYc’s artificial intelligence-based antibody discovery platform

•Preferred stock in RubrYc.

In connection with the entry into a Collaboration and License Agreement (the “RTX-003 License Agreement”) and a Collaboration, Option and License Agreement (the “Collaboration Agreement”) with RubrYc, as described in the August 2021 Form 8-K, the Company entered into a Stock Purchase Agreement (“Stock Purchase Agreement”) with RubrYc whereby it purchased 1,909,563 shares of RubrYc’s Series A-2 preferred stock (“Series A-2 Preferred”) for $5,000,000 and agreed to acquire an additional 954,782 shares of RubrYc’s Series A-2 Preferred for $2,500,000 in the event certain conditions set forth in the Stock Purchase Agreement are satisfied as of December 1, 2021. In connection with the Stock Purchase Agreement, the Company entered into the RubrYc Therapeutics, Inc. Second Amended and Restated Investors’ Rights Agreement (the “Investors’ Rights Agreement”), RubrYc Therapeutics, Inc. Second Amended and Restated Voting Agreement (the “Voting Agreement”) and the RubrYc Therapeutics, Inc. Second Amended and Restated Right of First Refusal and Co-Sale Agreement (the “Right of First Refusal and Co-Sale Agreement”).

On March 16, 2022, pursuant to the Stock Purchase Agreement, and upon the satisfaction of the conditions set forth therein, the Company acquired an additional 954,782 shares of RubrYc’s Series A-2 preferred stock for $2.5 million.

The rights, preferences of and privileges of the RubrYc Series A-2 Preferred Stock (“Series A-2 Preferred”) are set forth in the Third Amended and Restated Certificate of Incorporation of RubrYc Therapeutics, Inc. (the “Amended RubrYc COI”), and include a preferential eight percent (8%) dividend, senior rights on liquidation, the right to elect a Series A-2 Preferred director for as long as the Company holds at least 1,500,000 shares of RubrYc stock, the right to vote on an as-converted basis, certain anti-dilution and other protective provisions, the right to convert the Series A-2 Preferred into shares of RubrYc common stock at the Company’s option, and mandatory conversion of the Series A-2 Preferred into shares of RubrYc common stock upon (a) the closing of a firm-commitment underwritten public offering to the public pursuant to an effective registration statement under the Securities Act of 1933, as amended, for shares of RubrYc common stock at a per share price of at least five (5) times the Series A-2 Original Issue Price (as defined in the Amended RubrYc COI) and resulting in at least $30,000,000 of gross proceeds to RubrYc or (b) such other date, time or event, specified by vote or written consent of the majority of the aggregate voting power, on an as-converted basis, of the RubrYc Series A preferred stock (“Series A Preferred” and together with the Series A-2 Preferred, the “Senior Preferred Stock”) and Series A-2 Preferred.

The Right of First Refusal and Co-Sale Agreement gives RubrYc the right of first refusal on stock sales by key holders, generally defined as founders, and a second right of first refusal and a co-sale right to specified other investors, including certain holders of Senior Preferred Stock and the Company.

The Investors’ Rights Agreement provides the holders of Senior Preferred Stock with, among things: (i) demand registration rights, under specified circumstances; (ii) piggyback registration rights in the event of a company registered offering; (iii) lock-up and market-standoff obligations following a registered underwritten public offering; (iv) preemptive rights on company offered securities; and (v) additional protective covenants that require the approval at least two of the three directors elected by the holders of the Senior Preferred Stock .

Pursuant to the Voting Agreement, certain RubrYC stockholders are contractually obligated to, among other things, vote for and maintain the authorized number of directors at five members, one of which the Company has the contractual right to elect subject to the conditions set forth above.

The foregoing summary descriptions of the Collaboration Agreement, the RTX-003 License Agreement, the Stock Purchase Agreement, the Investors’ Rights Agreement, the Voting Agreement, the Right of First Refusal and Co-Sale Agreement and Amended RubrYc COI are not complete and are qualified in their entirety by reference to the full text of the Collaboration Agreement, the Collaboration and License Agreement, the Stock Purchase Agreement, the Investor Rights Agreement, the Voting Agreement, the Right of First Refusal and Co-Sale Agreement and Amended RubrYc COI, copies of which are filed as Exhibits 10.1, 10.2, 10.3, 10.4, 10.5 and 10.6 and 99.2 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are furnished with this Current Report on Form 8-K.


Exhibit Number		Exhibit Description
10.1 †*		Collaboration, Option and License Agreement, dated August 23, 2021, by and between iBio, Inc. and RubrYc Therapeutics, Inc. (incorporated by reference to the Form 8-K filed with the Securities and Exchange Commission on August 27, 2021 (File No. 001-35023)
10.2 †*		Collaboration and License Agreement, dated August 23, 2021, by and between iBio, Inc. and RubrYc Therapeutics, Inc. (incorporated by reference to the Form 8-K filed with the Securities and Exchange Commission on August 27, 2021 (File No. 001-35023)
10.3†*		Stock Purchase Agreement, dated August 23, 2021, by and between iBio, Inc. and RubrYc Therapeutics, Inc. (incorporated by reference to the Form 8-K filed with the Securities and Exchange Commission on August 27, 2021 (File No. 001-35023)
10.4†*		Second Amended and Restated Investor Rights Agreement, dated August 23, 2021, by and among RubrYc Therapeutics, Inc. and certain investors (incorporated by reference to the Form 8-K filed with the Securities and Exchange Commission on August 27, 2021 (File No. 001-35023)
10.5†*		Second Amended and Restated Voting Agreement, dated August 23, 2021, by and among RubrYc Therapeutics, Inc. and certain investors (incorporated by reference to the Form 8-K filed with the Securities and Exchange Commission on August 27, 2021 (File No. 001-35023)
10.6†*		Second Amended and Restated Right of First Refusal and Co-Sale Agreement, dated August 23, 2021, by and among RubrYc Therapeutics, Inc. and certain investors (incorporated by reference to the Form 8-K filed with the Securities and Exchange Commission on August 27, 2021 (File No. 001-35023)
99.1		iBio, Inc. Investor Presentation dated March 2022.
99.2		Third Amended and Restated Certificate of Incorporation of RubrYc Therapeutics, Inc. (incorporated by reference to the Form 8-K filed with the Securities and Exchange Commission on August 27, 2021 (File No. 001-35023)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally to the SEC a copy of any omitted schedule upon request.

†The Company has omitted certain portions of the Collaboration, Option and License Agreement and the Collaboration and License Agreement, Stock Purchase Agreement, Investors’ Rights Agreement, Voting Agreement, and Right of First Refusal and Co-Sale Agreement in accordance with Item 601(b)(10) of Regulation S-K. The Company agrees to furnish unredacted copies of these Exhibits to the SEC upon request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	IBIO, INC.

Date: March 18, 2022	By:	/s/ Thomas F. Isett
		Name:	Thomas F. Isett
		Title:	Chief Executive Officer

Exhibit 99.1

2 Forward - Looking Statements Certain statements in this presentation constitute "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended .. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward - looking statements .. These forward - looking statements are based upon current estimates .. While the Company believes these forward - looking statements are reasonable, undue reliance should not be placed on any such forward - looking statements, which are based on information available to us on the date of this presentation .. These forward - looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward - looking statements .. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to obtain regulatory approvals for commercialization of its product candidates, including its COVID - 19 vaccines and IBIO - 101 , or to comply with ongoing regulatory requirements, regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, its ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, competition, its ability to retain its key employees or maintain its NYSE American listing, and the other factors discussed in the Company’s most recent Annual Report on Form 10 - K and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10 - Q and 8 - K .. The information in this presentation is provided only as of today, and we undertake no obligation to update any forward - looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law .. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction ..

iBio : Growing Tomorrow’s Biologics Discovery Platform Novel screening capabilities with AI - driven design FastPharming Platform Proprietary plant - based protein expression system Development & Manufacturing Services Delivering speed, scalability, and sustainability Proprietary Pipeline Addressing cancer, fibrosis & infectious diseases 3

Only ~5 in 5,000 drug concepts reach the clinic Program Failures 4 Unique Solution for Some of the Industry’s Biggest Problems 1i iBio estimates; 2 Belkhir, L., et. al. (2018) “Carbon footprint of the global pharmaceutical industry and relative impact of its major players” .. J Cleaner Production 214:185 - 194 >1 year & ~$3 - 7M for scalable bioprocess & Ph1 material 1 Time / Cost Biopharmaceutical Development Challenges Drug industry is 55% more emissions intensive than the auto industry 2 Biomanufacturing Glycaneering ™ SOLUTIONS Dev/ Mfg Services Our Solutions 1 2 3

5 Green Protein Expression System 130,000 sf Facility 1 Bacterial Infiltration (Transient Transfection) Protein Production Harvesting Purification & Vialing Seeding & Growth Mobilization Gene Cloning 2 3 4 5

6 The Speed & Scalability of FastPharming Potentially Enables a Faster, More Efficient Path to the Clinic Time to Drug Substance may vary and does not include product - specific process and assay development work. Mammalian cell culture timelines shown are for illustrative purposes only based upon competitive data from publicly available so urces. Actual timelines may vary. brings the capability to avoid the significant cost and time associated with selecting, developing & banking mammalian cell lines Master Cell Bank (Mammalian) Drug Substance Manufacture Drug Substance Manufacture Mammalian Cell Culture Master Cell Bank (Bacterial) months months Candidate Generation

7 iBio Platforms Potentially Enable More Promising Candidates to Reach the Clinic, Faster Industry Benchmarks to Reach IND 1 Success Rate: <5 in 5,000 Time: >5 Years Cost: >$20M Current Drug Development Challenge Drug Discovery Preclinical 3 - 6 Years FDA Review Scale - up to MFG Post - Marketing Surveillance NDA Submitted ..5 - 2 Years Indefinite 20 - 100 100 - 500 1000 - 5000 6 - 7 Years Clinical Trial IND Submitted Pre - Discovery Phase 1 Phase 2 Phase 3 Number of Volunteers 1 FDA - Approved Drug ~5,000 – 10,000 Compounds 250 5 1 Paul, et al. NatureReviews Drug Discovery. (2010) 9, 203 – 214 + Glycaneering Technology TM Enabling production of high - quality, potent, and efficiently scalable anti - cancer monoclonal antibodies Stronger ADCC

8 1 17th Annual Report and Summary of Biopharmaceutical Manufacturing Capacity and Production https://www.biopharma.com/TRENDS.pdf .. 2 Seeds, stone wool, and purified water FastPharming : Reducing Single - Use Plastic Disposables in Bioprocessing The FastPharming Expression System uses all - natural raw materials 2 VS >85% of pre - commercial bioprocesses involve single - use plastic disposables 1

9 Our Platform Technologies Fueling a Growing Pipeline

Therapeutics Oncology & Fibrosis

THERAPEUTICS Natural Killer Cell Indiscriminate depletion of T reg + T eff RTX - 003 (IBIO - 101) Stimulates Anti - tumor Immunity via anti - CD25 T reg Depletion 11 T reg = Regulatory T Cells; T eff = Effector T Cells; ADCC = Antibody Dependent Cellular Cytotoxicity T eff JAK JAK 1 st gen anti - CD25 antibodies à blocked IL - 2 pathways RTX - 003 JAK JAK Tumor Tumor T eff T reg JAK JAK Preferential T reg depletion 1 st gen CD25 mAbs depleted immuno - suppressive T reg and immuno - stimulatory T eff Limited efficacy 2 nd gen RTX - 003 selectively targets T regs without blocking IL - 2 signaling to T effs Strong preclinical anti - tumor response IL - 2 CD25 (IL - 2R α ) JAK JAK IL - 2 T reg IL - 2 signaling Proliferation ADCC JAK JAK

THERAPEUTICS 12 RTX - 003 Inhibits Tumor Growth, Alone and in Combination 1 In vivo xenograft mouse model of lymphoma; Administration: 3x / week, i.p. ; n=5 per group 2 In vivo transgenic hCD25 mouse model; Admin: i.p. 3X / week at a single dose (1.5 mg/Kg) in combination with 2.5 mg/Kg of anti - mouse PD - 1 antibody; n=5/group Greater potency achievable with afucosylated version attainable using Glycaneering Technology TM 0 5 1 0 1 5 2 0 2 5 0 5 0 0 1 0 0 0 1 5 0 0 2 0 0 0 2 5 0 0 D a y s P o s t E n g r a f t m e n t T u m o r S i z e ( m m 3 ) P B S D 1 1 3 m g / k g D 1 1 1 m g / k g D 1 1 0 .. 3 m g / k g PBS (Vehicle) 0.3 mg/kg 1.0 mg/kg 3.0 mg/kg Lymphoma Xenograft Model 1 Adenocarcinoma Model 2 0 3 6 9 1 2 1 5 1 8 2 1 2 4 2 7 3 0 3 3 3 6 0 1 0 0 0 2 0 0 0 3 0 0 0 4 0 0 0 D a y s P o s t G r o u p i n g T u m o r v o l u m e m m 3 P D 1 5 m g / k g D 1 1 1 .. 5 + P D 1 5 m g / k g P B S D 1 1 1 .. 5 m g / k g PBS (Vehicle) 1.5 mg/kg RTX - 003 5.0 mg/kg PD1 mAb 1.5 mg/kg RTX - 003 + 5.0 mg/kg PD1 mAb Monotherapy reduced tumor growth in a dose - dependent manner RTX - 003 + anti - PD - 1 antibody reduced tumor growth and caused regression

THERAPEUTICS 13 Deploying AI - based Target ID & Glycaneering in Immuno - Oncology to Create More, Higher - Quality, Shots - on - Goal Speed - to - Clinic & Readily Scalable Access to RubrYc AI Discovery Platform Glycaneering Technology As programs advance through preclinical testing, iBio has additional opportunities to partner molecules and supply with FastPharming Services De - risking Discovery & Development Process iBio Discovery & Dev Approach Traditional BioPharma Pipeline

THERAPEUTICS 14 IBIO - 100: Promising Anti - Fibrotic Therapeutic Candidate 1 Idiopathic Pulmonary Fibrosis: Disease Landscape & Forecast, Decision Resources, April 6, 2020; 2 iBio data on file Involved in ~45% of U.S. deaths from all diseases No cures: organ transplants for some late - stage diseases Limited number of palliative treatments (most indications) Many patients forego available treatments due to poor tolerability Market for current drugs for idiopathic pulmonary fibrosis alone is presently >$1.8B 1 Fibrotic Disorders Endostatin E4 peptide that reduces fibrosis by impacting extracellular matrices Pre - clinical data shows reduced fibrosis in scleroderma/IPF models & human lung explants IBIO - 100 Orphan Drug Designation for systemic scleroderma received Intrinsic properties could enable an oral route - of - administration 100 µ g I BIO - 100 3x/week Fibrotic Tissue Bleomycin Pre - Clinical Model 2 Human Lung Tissue From End - Stage Disease at Transplant 2

Vaccines Human Health: COVID - 19 Animal Health: CSFV

VACCINES 16 COVID - 19 1 Johns Hopkins Coronavirus Resource Center (accessed 16 March 2022) …while experts sound the alarm “V accination strategies based on repeated booster doses of the original vaccine composition are unlikely to be appropriate or sustainable." Boosters are “not something that should be repeated constantly”… it could lead to "problems with immune response." 1 The pandemic continues…

VACCINES Lower cost vaccines & alternative routes of administration 17 Experts Calling for Approaches Like iBio’s “ DAVi ” Vaccine Design 1 Borio , Bright, and Emanuel, A National Strategy for COVID - 19 Medical Countermeasures , JAMA. 2022;327(3):215 – 216 Second - generation IBIO - 202 development effort seeks to address D urability, A ccess, and V ariant - i nclusion Antigen - adjuvant combos that may deliver long - lasting immunity Less mutable antigens to protect against emerging variants Durability Variant - inclusion Access IBIO - 202 D urability V ariant - i nclusion A ccess A National Strategy for COVID - 19 Medical Countermeasures – Vaccines & Therapeutics January 2022 Luciano Borio , Rick Bright, and Ezekiel Emanuel “The government should accelerate efforts to develop a universal coronavirus vaccine to protect against known coronaviruses, in cluding SARS - CoV - 2. A more broadly protective vaccine would allow the world to limit the effects of emerging variants and nimbly react to novel coronaviruses that are likely to emerge in the future. …the government needs to facilitate further development of vaccines, including alternate dosing and administration approaches – some examples include… skin patches that decrease the complex logistical challenges of vaccination campaigns” 1

VACCINES 18 IBIO - 202 Nucleocapsid [N] - based Subunit Vaccine May Complement to Current and Future Spike [S] - based Vaccines 1 Dai, L. & Gao, G. F. Viral targets for vaccines against COVID - 19. Nature Reviews Immunology 21, 73 – 82 (2021); 2 Fielding CA, et.al .., ADNKA overcomes SARS - CoV2 - mediated NK cell inhibition through non - spike antibodies. bioRxiv , (April 2021) The antigen is produced in our rapidly scalable FastPharming System N - antigen more effective than S in stimulating Natural Killer cell activation 2 Prospectively suitable for delivery via routes other than intramuscular injection N protein function is critical to viral genome packaging and is more highly conserved than the S protein. Thus, new viral variants may be less likely to escape N - based vaccines 1

VACCINES 19 IBIO - 202 Preclinical Data Shows Potential for Protective Humoral & Cell - mediated Immune Responses C t r l .. I B I O - 2 0 2 0 1 2 3 4 I F N - g S e c r e t i n g c e l l s / 1 0 6 ✱✱✱✱ High number of N - specific IFN g secreting T cells indicates immune activation C t r l .. I B I O - 2 0 2 0 1 2 3 4 I L - 5 S e c r e t i n g c e l l s / 1 0 6 n s C t r l .. I B I O - 2 0 2 0 1 2 3 4 I L - 1 3 S e c r e t i n g c e l l s / 1 0 6 n s Low number of IL - 5 & IL - 13 secreting cells indicates T - cell priming Better Immune Response Increasing Antibody Titer 1/100 1/6400 no adjuvant poor adjuvant Selected, optimal adjuvant Increasing Blood Dilution Adjuvanted IBIO - 202 causes strong anti - N titers IBIO - 202 desired Th1 skew indicative of a protective, not inflammatory, immune response Ctrl. Adjuv .. 2 Poor Adjuvant IgG1 (Th2 response) IgG2C (desired Th1 response) Selected, optimal Adjuvant Adjuv .. 1 Antibody Response T - cell Response iBio data on file

VACCINES 20 Emerging Studies Reinforce Value of IBIO - 202’s Design 1 Kundu, R., Narean, J.S., Wang, L. et al. Cross - reactive memory T cells associate with protection against SARS - CoV - 2 infection in COVID - 19 contacts. Nat Commun 13, 8 0 (2022) 2 Cohen, et al. Cell Reports Medicine. July 2021 Potential for a pan - betacoronavirus vaccine strengthening Nucleocapsid - based induction of mature T cells adds benefit to more rapid containment of infection as variants overtake the prevailing strains 2 Our antigen has an epitope predicted to provide cross - protection to other betacoronaviruses “ N - , not S - , reactive T cells play a protective role ” 1 IgG Antibodies to Other Human Coronaviruses COVID - 19+ Pre - pandemic Time Immune Response Months 8 Beta CoV SARS - CoV - 1 Alpha CoV 254 COVID - 19+ patients 760 sampling visits SARS - CoV - 2 Specificities CD4 T Cell CD8 T Cell Spike 1 Spike 2 Env & Membrane Nucleocapsid ORF 3a, 6 ORF 7a, 7b, 8

VACCINES 9 4 2 1 N only (US & global companies) ■ N only (academic, government, ex - US) ■ S+N+M or other combination ■ S+N 21 IBIO - 202 Appears Differentiated in a Crowded Field 1 Dangi, Tanushree et al. “Combining spike - and nucleocapsid - based vaccines improves distal control of SARS - CoV - 2.” Cell reports vol. 36,10 (2021) 21 N - directed vaccines may provide protection from COVID’s neurological effects that S vaccines may not 1 Simpler N - only design could improve access with lower COGS Potential pan - betacoronavirus effects could obviate the need for spike antigen vaccination 169 16 Spike Only Nucleocapsid Source: GlobalData database of drugs in development by targeted antigen

Classical Swine Fever Animal Health

VACCINES 23 Classical Swine Fever [CSF] is a Significant World - Wide Economic Burden and Puts Major Export Markets at Risk • CSF is a priority agricultural biothreat • CSF poses a risk to $7.0B US swine exports • Only 38 countries are currently CSF - free • No vaccines are approved in the US (only for emergency use) • Current emergency use CSF vaccines have drawbacks Vaccination control programs are essential to manage outbreaks and regain trade status https:// www.oie.int / en /disease/classical - swine - fever/#ui - id - 2 o Modified live vaccines do not facilitate international trade o Recombinant vaccines are expensive

VACCINES 24 IBIO - 400 Offers Potential Benefits Over Current Alternatives • Provides single - dose protection against CSF • Is a low - cost alternative to current recombinant vaccines • Supports important trade requirements, unlike live virus vaccines • Potential to be the first CSF vaccine fully licensed by USDA CSF Virus A single dose of IBIO - 400 provides protection for pigs IBIO - 400: E2 protein subunit vaccine

In Summary

Our Leadership Team Brings Drug Development & Bioprocessing Experience 26 Tom Isett CEO & Chairman Martin Brenner , DVM, Ph.D. CSO Robert Lutz, MBA CFBO Randy Maddux , MBA COO Lisa Middlebrook CHRO

27 Strong and Growing IP Estate Provides Exclusivity for iBio’s Pipeline Issued Patents (30 U.S.) 104 Active Applications (10 U.S.) 29 More Applications progressing to filing Patent Protection Includes: • IP for iBio’s pipeline products and vaccines • IP related to the FastPharming Protein Expression System ® • Elements of Glycaneering Technology Platform ™ for advanced glycosylation controls in plants, including afucosylation for Antibody - Dependent Cellular Cytotoxicity [ADCC] Continuing to Aggressively Defend our Intellectual Property • Settled iBio v. Fraunhofer USA for $28M in May 2021

28 Financial Overview § Publicly traded (NYSEA: IBIO) since Jan 2008 § Approximately $57.4M in cash and cash equivalents plus investments in debt securities, excluding $5.9M of restricted cash (31 Dec 2021) § Approximately 218.0M common shares & 17M options, restricted stock units and warrants outstanding (31 Dec 2021) § Texas Manufacturing Facility § Purchased in Nov 2021 with approximately $22.4M debt (secured by the facility), $6M in cash, and 1.3M warrants § Evaluating sale - leaseback to extinguish the debt and recover cash § Current cash provides runway through Sept 30, 2023

29 Upcoming Milestones Human Health Program Next Milestone Subsequent Key Milestone IBIO - 400 Oral immunogenicity study results USDA Manufacturing Clearance Program Next Milestone Subsequent Key Milestone IBIO - 100 Completion of lead optimization IND - Enabling Study Initiation IBIO - 101 IND - enabling study initiation (mid 2022) IND IBIO - 202 IND - enabling study initiation IND (est. Dec 2022) Discovery Announce lead for 1 program 2 - 4 leads and targets announced Animal Health Program Next Milestone Subsequent Key Milestone FastPharming Comparability v. Mammalian for IBIO - 101 Validating 3 rd Party Contracts CDMO Services

30 iBio : Leveraging Capabilities to Create Shareholder Value Advancing our proprietary pipeline with FastPharming Manufacturing Partnering Providing better options for the $6B Bioprocess industry CDMO Services Vaccines Therapeutics Partnering Leveraging platform to seek attractive assets for in - licensing Therapeutics Selectively out - licensing assets and securing FastPharming supply contracts